WO2004074232A1 - 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases - Google Patents

1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
WO2004074232A1
WO2004074232A1 PCT/EP2004/001596 EP2004001596W WO2004074232A1 WO 2004074232 A1 WO2004074232 A1 WO 2004074232A1 EP 2004001596 W EP2004001596 W EP 2004001596W WO 2004074232 A1 WO2004074232 A1 WO 2004074232A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
chf
alkyl
branched
linear
Prior art date
Application number
PCT/EP2004/001596
Other languages
French (fr)
Other versions
WO2004074232A8 (en
Inventor
Luca Raveglia
Ilaria Peretto
Stefano Radaelli
Bruno Pietro Imbimbo
Andrea Rizzi
Gino Villetti
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20030311 external-priority patent/ITMI20030311A1/en
Priority claimed from ITMI20032068 external-priority patent/ITMI20032068A1/en
Priority to KR1020057014850A priority Critical patent/KR101088272B1/en
Priority to JP2006501896A priority patent/JP4472691B2/en
Priority to US10/546,190 priority patent/US7662995B2/en
Priority to DE602004016729T priority patent/DE602004016729D1/en
Priority to EP04712483A priority patent/EP1594833B1/en
Priority to KR1020117008239A priority patent/KR101152448B1/en
Priority to DK04712483T priority patent/DK1594833T3/en
Priority to AU2004213145A priority patent/AU2004213145B2/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Priority to SI200430900T priority patent/SI1594833T1/en
Priority to CA2514384A priority patent/CA2514384C/en
Priority to BRPI0407662A priority patent/BRPI0407662B8/en
Publication of WO2004074232A1 publication Critical patent/WO2004074232A1/en
Priority to NO20053855A priority patent/NO333118B1/en
Publication of WO2004074232A8 publication Critical patent/WO2004074232A8/en
Priority to HK06107643.0A priority patent/HK1087398A1/en
Priority to US12/647,069 priority patent/US8022250B2/en
Priority to US13/204,989 priority patent/US8314268B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C07C15/14—Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention concerns 1-phenylalkanecarboxylic acids, pro- drugs and bioisosters on the carboxylic moiety thereof.
  • the invention is also directed to a process for their preparation and the use thereof in the prevention or in the therapeutical treatment of neurodegenerative diseases, in particular Alzheimer's disease. INTRODUCTION
  • Alzheimer's disease is a neurodegenerative disorder characterized by atrophy of the cerebral cortex and by a massive loss of cortical neurons and cholinergic projections of the nucleus basalis towards the cortex. From a histopathologic point of view there is a diffuse presence of extracellular and perivascular neuritic plaques and intracellular neurofibrillary tangles in the cerebral parenchyma of Alzheimer patients.
  • Neuritic plaques are mainly composed of aggregates of a protein with 39-43 amino acid residues known as ⁇ -amyloid ( ⁇ A), and, depending on the numbers of aminoacids, A ⁇ 39 , A ⁇ 40 , A ⁇ 2 and A ⁇ 4 .
  • ⁇ A ⁇ -amyloid
  • NSAIDs non steroid anti-inflammatory drugs
  • COX cyclooxygenase
  • NSAIDs non steroid anti- inflammatory drugs
  • indomethacin, sulindac, ibuprofen and flurbiprofen can selectively reduce the production of the most neurotoxic isoform of ⁇ -amyloid peptide in cell cultures, namely the form containing 42 amino acids (A ⁇ 42 ), thus favouring the release of a less harmful isoform, A ⁇ 38 (Weggen et al., Nature 2001; 414 (6860): 212-6).
  • WO 01/78721 claims a method of preventing, delaying or reversing the progression of Alzheimer's disease by administering an A ⁇ 42 lowering agent, under conditions in which levels of A ⁇ 38 are increased and levels of A ⁇ 42 are left unchanged. Furthermore, methods and materials for identifying and developing A ⁇ 42 lowering agents and methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease, are disclosed. The examples concern indomethacin and flufenamic acid derivatives, but no examples concerning flurbiprofen derivatives are reported. Jantzen et al, J Neurosci 2002; 22: 2246-2254, described a flurbiprofen derivative capable of releasing nitric oxide. The paper generically states that flurbiprofen derivatives are apparently more efficacious than other NSAIDs in clearing ⁇ -amyloid deposits, but no mention concerning any A ⁇ 42 lowering selective activity is made.
  • novel derivatives having more selective and more potent inhibitory activity on the peptide A ⁇ 42 while inhibiting to a lesser extent, or not inhibiting at all, cyclooxygenase would be a significant improvement in therapies aimed at preventing the onset of Alzheimer's disease and/or at delaying the cognitive decline that represent an early stage disease.
  • Substituted l-phenyl-2,2-dialkyl carboxylic derivatives were described as anti-inflammatory, analgesic and antipyretic agents in GB 1,198,212, US 3,978,071, US 757,136, GB 1,352,723, JP49100089 and JP 50046669.
  • 3-Halo-4-alkyl- or cycloalkyl- substituted 1-phenylcycloalkanecarboxylic derivatives were described in JP-4,7047,375 and FR-2, 012,285, as substances with the same activity.
  • the present invention concerns 1-phenylalkanecarboxylic acids, their pro-drugs, and bioisosters on the carboxylic moiety, the process for the preparation thereof, pharmaceutical compositions containing them and the use thereof in the prevention or therapeutical treatment of neurodegenerative diseases, in particular Alzheimer's disease.
  • the compounds of the invention inhibit the release of A ⁇ 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes.
  • the present invention is directed to compounds of general formula (I):
  • R and R are the same and are selected from the group of linear or branched C ⁇ -C 4 alkyl; otherwise they form a 3 to 6 carbon atoms ring with the carbon atom to which they are linked;
  • G is: a COOR" group wherein R" is H, linear or branched C C alkyl, C 3 -C 6 cycloalkyl or ascorbyl; a CONH 2 or a CONHSO 2 R'" group wherein R'" is linear or branched C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; - a tetrazolyl residue;
  • R 2 is H, CF 3; OCF 3 or a halogen selected from the group of F, Cl, Br, I, preferably fluorine.
  • Ar is a group of formula
  • R 3 represents one or more groups independently selected from: halogen as previously defined; CF 3 ;
  • R 4 is CF 3 , linear or branched C 2 -C 6 alkenyl or alkynyl; benzyl; phenyl optionally substituted with one or more of the following groups: halogen, CF 3 , OCF 3 , OH, linear or branched C C 4 alkyl; a saturated eterocycle with at least 4 carbon atoms and at least 1 heteroatom; C 3 -C 8 cycloalkyl in turn optionally substituted with one or more of the following groups: linear or branched C C alkyl, CF 3 or OH;
  • Ar is an eterocycle ring selected from the group of thiophene, benzothiophene, dibenzothiophene, thianthrene, pyrrole, pyrazole, furan, benzofuran, dibenzofuran, indole, isoindole, benzofurane, imidazole, benzoimidazole, oxazole, isoxazole, benzoxazole, thiazole, pyridine, pyrimidine, pyrazine, pyridazine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyrazole, pyran, benzopyran, pyrrolizine, phtalazine, 1,5-naphthyridine, 1,3-dioxole, 1,3-benz
  • a first group of preferred compounds is that in which: R and R 1 form a 3 carbon atoms ring with the carbon atom to which they are linked;
  • R 2 is fluorine
  • G is COOR", wherein R" is H, linear or branched C r C 4 alkyl, C 3 -C 6 cycloalkyl or ascorbyl; Ar is phenyl as defined above.
  • a second group of preferred compounds is that in which: R and R 2 form a 3 carbon atoms ring with the carbon atom to which they are linked;
  • R 2 is fluorine
  • G is CONH 2 or CONHSO 2 R'" wherein R'" is linear or branched C r C 4 alkyl or C 3 -C 6 cycloalkyl
  • Ar is phenyl as defined above.
  • a third group of preferred compounds is that in which: both R and R ! are methyl; R 2 is fluorine;
  • G is COOR" wherein R" is as defined above; Ar is phenyl as defined above.
  • a fourth group of preferred compounds is that in which: both R and R t are methyl; R 2 is fluorine;
  • G is CONH 2 or CONHSO 2 R'", wherein R"' is as defined above; Ar is phenyl as defined above.
  • a fifth group of preferred compounds is that in which: R and R t form a 3 carbon atoms ring with the carbon atom to which they are linked;
  • R 2 is fluorine
  • G is COOR" wherein R" is as defined above; Ar is a heterocycle as defined above.
  • a sixth group of preferred compounds is that in which: both R and Ri are methyl;
  • R 2 is fluorine
  • G is COOR" wherein R" is as defined above; Ar is a heterocycle as defined above.
  • CHF 5071 l-[2-fluoro-4'-(tetrahydropyran-4-yloxy)biphenyl-4-yl]-cyclopropane- carboxylic acid
  • CHF 5073 l-(2,3',4'-trifluorobiphenyl-4-yl)cyclopropanecarboxylic acid
  • CHF 5073 l-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid
  • CHF 5079 l-[2-fluoro-4'-(tetrahydropyran-4-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
  • CHF 5080 l-[2-fluoro-4'-(4-oxo-cyclohexyl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
  • CHF 5104 l-(2,2',4"-trifluoro[l,r:4',l"-tert-phenyl]-4-yl)-cyclopropanecarboxylic acid
  • CHF 5105 l-(2,3'-difluoro-4"-hydroxy[l, r:4', l "-tert-phenyl]-4-yl)-cyclopropane- carboxylic acid
  • CHF 5106 l-(2,2'-difluoro-4"-hydroxy[l, :4',l"-tert- ⁇ henyl]-4-yl)-cyclopropane- carboxylic acid
  • CHF 5125 2-(2-fluoro-3',5'-bis(chloro)biphen-4-yl)propionic acid amide
  • a more preferred group of compounds is that in which R and Ri form a
  • R 2 is fluorine
  • G is COOH;
  • Ar is phenyl substituted with one or more groups in such a way as that the log
  • the invention also relates to the pharmaceutically acceptable salts and esters prepared in order to increase the crossing of the hemato-encephalic barrier.
  • a further object of the present invention are the compounds of formula
  • (I) as medicaments in particular the use thereof in the preparation of pharmaceutical compositions for the treatment and/or the prevention of neurodegenerative diseases such as Alzheimer's disease.
  • Still a further object of the invention are solid or liquid pharmaceutical compositions, preferably for the oral use, comprising at least one compound of formula (I) in admixture with pharmaceutically acceptable excipients and/or carriers, for example those described in Remington's Pharmaceutical Sciences
  • R, R ⁇ and R 2 are as defined above and X is bromine or iodine, preferably iodine, with a boronic acid or ester ArB(OL) 2 in which L is an alkyl chain, under the conditions reported in Scheme 1.
  • R and R j _ are straight or branched Cr-C alkyl (Ha).
  • Said compounds can be prepared according to the synthetic route shown in Scheme 2 , starting from the arylacetic acids of formula (III) in which R and R 2 are as defined above and X is bromine or iodine.
  • the acid of formula (III) is esterified, alkylated, and optionally hydrolysed if the group G in the final product is COOH.
  • Said compounds are either commercially available, or can be prepared according to the synthetic route reported in Scheme 3 in which n is an integer of 1 to 4.
  • the compounds of formula (I) wherein G is COOR", where R" is linear or branched C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl or ascorbyl, can be prepared by esterifying the compounds of formula (I) in which G is COOH.
  • the compounds of formula (I) in which G is CONH 2 or CONHSO 2 R'" where R'" is linear or branched C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl can be prepared by reaction of the corresponding esters with NH 3 or the amine NH 2 SO 2 R"'.
  • the compounds of formula (I) in which G is tetrazolyl can be prepared from compounds of formula (I) according to known methods, for example transforming the carboxylic acid into amide, dehydrating the amide to nitrile and reacting the latter with tributyltin azide.
  • a suspension of 4-bromo-3-fluorophenylcyclo ⁇ ropanenitrile (21 mmoles) in methanol (10 ml) is added with a 35% NaOH aqueous solution (40 ml) and a 35% H 2 O 2 aqueous solution (3 ml), then is refluxed for 4 hours, cooled at room temperature and added with 2N HCl (250 ml).
  • the precipitated solid is collected by filtration and redissolved in a 5% NaHCO 3 aqueous solution (300 ml).
  • H4- 15x cells human neuroglioma cells transfected with the human gene encoding for the precursor of ⁇ -amyloid protein APP695
  • H4- 15x cells were cultured in flasks (in incubator at 37°C, under aqueous vapour saturated atmosphere with 5% carbon dioxide), in the presence of hygromycin and blasticidin, which maintain the selective pressure for the cells continuously expressing the gene of interest.
  • the cells When the cells reached about 90% confluency, they were collected and re-seeded in 24 wells plates (2 x 10 5 cells each), in 0.5 ml of complete culture medium. After approx. 24 hours, when the cells had adhered to the well surface and reached confluency, the medium of each well was replaced with 0.5 ml of fresh culture medium, supplemented with a compound (I) to 100 micromolar final concentration. Each tested concentration was repeated in triplicate. The molecules used for the treatment were previously dissolved in dimethylsulfoxide (DMSO) or in a dimethylsulfoxide/water mixture, the final concentration of DMSO in the wells not exceeding 1%.
  • DMSO dimethylsulfoxide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.

Description

1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
The present invention concerns 1-phenylalkanecarboxylic acids, pro- drugs and bioisosters on the carboxylic moiety thereof. The invention is also directed to a process for their preparation and the use thereof in the prevention or in the therapeutical treatment of neurodegenerative diseases, in particular Alzheimer's disease. INTRODUCTION
Alzheimer's disease is a neurodegenerative disorder characterized by atrophy of the cerebral cortex and by a massive loss of cortical neurons and cholinergic projections of the nucleus basalis towards the cortex. From a histopathologic point of view there is a diffuse presence of extracellular and perivascular neuritic plaques and intracellular neurofibrillary tangles in the cerebral parenchyma of Alzheimer patients.
Neuritic plaques are mainly composed of aggregates of a protein with 39-43 amino acid residues known as β-amyloid (βA), and, depending on the numbers of aminoacids, Aβ39, Aβ40, Aβ 2 and Aβ4 .
In addition to these histopathologic lesions, there is lack in some neurotransmitters, particularly acetylcholine, serotonin, noradrenalin, dopamine, glutamate and substance P. The pharmacological approaches aimed at increasing acetylcholine cerebral levels, mainly through acetylcholine- esterase inhibitors, attained poor results from the clinical standpoint, or anyhow results which cannot significantly prevent the progress of the disease. For this reason, in recent years interest has been focused on the mechanisms of formation of the main pathologic lesions in the brain of the patients, namely both neuritic plaques and neurofibrillary tangles, and more effective therapeutical approaches have been looked for. PRIOR ART
Epidemiological studies evidenced that chronic administration of non steroid anti-inflammatory drugs (NSAIDs) significantly decreases the onset of Alzheimer's disease in the population regularly taking these drugs. The mechanism underlying such NSAID preventive action has not been fully elucidated yet, but is apparently connected with their ability of inhibiting cyclooxygenase (COX) enzymes.
More recently, a novel pharmacological action of some non steroid anti- inflammatory drugs (NSAIDs) has been described: indomethacin, sulindac, ibuprofen and flurbiprofen can selectively reduce the production of the most neurotoxic isoform of β-amyloid peptide in cell cultures, namely the form containing 42 amino acids (Aβ42), thus favouring the release of a less harmful isoform, Aβ38 (Weggen et al., Nature 2001; 414 (6860): 212-6). However, the inhibition of the production of Aβ42, which can be ascribed to the interaction of these drugs with γ-secretase (a macromolecular/multiprotein enzymatic complex with aspartyl-protease activity) has been observed in vitro at very high concentrations. Plasma and cerebral levels corresponding to the dosages used in the in vitro experimentation could significantly increase in treated patients the risk of side effects typical of COX inhibitors, such as gastrointestinal bleeding and perforating ulcers.
WO 01/78721 claims a method of preventing, delaying or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent, under conditions in which levels of Aβ38 are increased and levels of Aβ42 are left unchanged. Furthermore, methods and materials for identifying and developing Aβ42 lowering agents and methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease, are disclosed. The examples concern indomethacin and flufenamic acid derivatives, but no examples concerning flurbiprofen derivatives are reported. Jantzen et al, J Neurosci 2002; 22: 2246-2254, described a flurbiprofen derivative capable of releasing nitric oxide. The paper generically states that flurbiprofen derivatives are apparently more efficacious than other NSAIDs in clearing β-amyloid deposits, but no mention concerning any Aβ42 lowering selective activity is made.
In this therapeutical scenario, and in the light of the potential problems of conventional NSAIDs, novel derivatives having more selective and more potent inhibitory activity on the peptide Aβ42 while inhibiting to a lesser extent, or not inhibiting at all, cyclooxygenase would be a significant improvement in therapies aimed at preventing the onset of Alzheimer's disease and/or at delaying the cognitive decline that represent an early stage disease.
Substituted l-phenyl-2,2-dialkyl carboxylic derivatives were described as anti-inflammatory, analgesic and antipyretic agents in GB 1,198,212, US 3,978,071, US 757,136, GB 1,352,723, JP49100089 and JP 50046669. 3-Halo-4-alkyl- or cycloalkyl- substituted 1-phenylcycloalkanecarboxylic derivatives were described in JP-4,7047,375 and FR-2, 012,285, as substances with the same activity.
In the paper from Kuzuna S et al (Takeda Kenkyushoho 1975, 34, 467-
473) dealing with a structure-activity study of a series of phenylacetic derivatives, it is generically stated that the introduction of a cyclopropane group at the position of α carbon atom decreases the anti-inflammatory and analgesic activities.
In WO 99/41224 novel biaryl-acetic acid derivatives with anti- inflammatory activity as cyclooxygenase-2 inhibitors, useful for the treatment of a number of diseases, including Alzheimer's disease, are claimed. SUMMARY OF THE INVENTION
The present invention concerns 1-phenylalkanecarboxylic acids, their pro-drugs, and bioisosters on the carboxylic moiety, the process for the preparation thereof, pharmaceutical compositions containing them and the use thereof in the prevention or therapeutical treatment of neurodegenerative diseases, in particular Alzheimer's disease.
The compounds of the invention inhibit the release of Aβ42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compounds of general formula (I):
Figure imgf000005_0001
wherein:
R and R are the same and are selected from the group of linear or branched Cι-C4 alkyl; otherwise they form a 3 to 6 carbon atoms ring with the carbon atom to which they are linked; G is: a COOR" group wherein R" is H, linear or branched C C alkyl, C3-C6 cycloalkyl or ascorbyl; a CONH2 or a CONHSO2R'" group wherein R'" is linear or branched C1-C4 alkyl or C3-C6 cycloalkyl; - a tetrazolyl residue;
R2 is H, CF3; OCF3 or a halogen selected from the group of F, Cl, Br, I, preferably fluorine.
Ar is a group of formula
Figure imgf000005_0002
wherein R3 represents one or more groups independently selected from: halogen as previously defined; CF3;
C3-C8 cycloalkyl optionally substituted with one or more C1-C4 alkyl and/or oxo groups;
CH— CH ; CN;
CH2OH; methylendioxy or ethylendioxy; - NO2 phenyl optionally substituted with one or more of the following groups: halogen; CF3; OCF3; OH; linear or branched C1-C4 alkyl; a saturated eterocycle with at least 4 carbon atoms and at least 1 heteroatom; C3-C8 cycloalkyl in turn optionally substituted with one or more of the following groups linear or branched C C alkyl, CF3 or OH;
OR4 or NHCOR4 wherein R4 is CF3, linear or branched C2-C6 alkenyl or alkynyl; benzyl; phenyl optionally substituted with one or more of the following groups: halogen, CF3, OCF3, OH, linear or branched C C4 alkyl; a saturated eterocycle with at least 4 carbon atoms and at least 1 heteroatom; C3-C8 cycloalkyl in turn optionally substituted with one or more of the following groups: linear or branched C C alkyl, CF3 or OH;
SR5, SO2R5 or COR5 wherein R5 is linear or branched Cι-C6 alkyl; otherwise Ar is an eterocycle ring selected from the group of thiophene, benzothiophene, dibenzothiophene, thianthrene, pyrrole, pyrazole, furan, benzofuran, dibenzofuran, indole, isoindole, benzofurane, imidazole, benzoimidazole, oxazole, isoxazole, benzoxazole, thiazole, pyridine, pyrimidine, pyrazine, pyridazine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyrazole, pyran, benzopyran, pyrrolizine, phtalazine, 1,5-naphthyridine, 1,3-dioxole, 1,3-benzodioxole, optionally substituted with one or more groups R3 as defined above; pharmaceutically acceptable salts and esters thereof.
A first group of preferred compounds is that in which: R and R1 form a 3 carbon atoms ring with the carbon atom to which they are linked;
R2 is fluorine;
G is COOR", wherein R" is H, linear or branched CrC4 alkyl, C3-C6 cycloalkyl or ascorbyl; Ar is phenyl as defined above.
A second group of preferred compounds is that in which: R and R2 form a 3 carbon atoms ring with the carbon atom to which they are linked;
R2 is fluorine; G is CONH2 or CONHSO2R'" wherein R'" is linear or branched CrC4 alkyl or C3-C6 cycloalkyl; Ar is phenyl as defined above.
A third group of preferred compounds is that in which: both R and R! are methyl; R2 is fluorine;
G is COOR" wherein R" is as defined above; Ar is phenyl as defined above.
A fourth group of preferred compounds is that in which: both R and Rt are methyl; R2 is fluorine;
G is CONH2 or CONHSO2R'", wherein R"' is as defined above; Ar is phenyl as defined above.
A fifth group of preferred compounds is that in which: R and Rt form a 3 carbon atoms ring with the carbon atom to which they are linked;
R2 is fluorine;
G is COOR" wherein R" is as defined above; Ar is a heterocycle as defined above.
A sixth group of preferred compounds is that in which: both R and Ri are methyl;
R2 is fluorine;
G is COOR" wherein R" is as defined above; Ar is a heterocycle as defined above.
Particularly preferred are the following compounds:
2-methyl-2(2-fluoro-4'-trifluoromethylbiphen-4-yl)propionic acid (CHF
4810);
2-methyl-2(2-fluoro-4'cyclohexyl biphen-4-yl)propionic acid (CHF 4961); 1 -(2-fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid
(CHF 5022);
1 -(4'-cyclohex l-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5023);
1 -(4'-benzyloxy-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF 5042);
1 -(2-fluoro-4'-isopropyloxybiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5044);
1 -(2-fluoro-3 '-trifluoromethoxybiphenyl-4-yl)cyclopropanecarboxylic acid
(CHF 5045); 1 -(2-fluoro-4'-trifluoromethoxybiphenyl-4-yl)cyclopropanecarboxylic acid
(CHF 5046);
1 -(2-fluoro-3 '-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid
(CHF 5058); 1 -(4'-cyclopentyl-2-fluorobiphenyl-4-yl)cycloρropanecarboxylic acid (CHF
5059); l-(4'-cycloheptyl-2-fluorobiphenyl-4-yl)cycloρropanecarboxylic acid (CHF
5060); l-(2'-cyclohexyl-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5061);
1 -(2-fluoro-4'-hydroxybiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5070); l-[2-fluoro-4'-(tetrahydropyran-4-yloxy)biphenyl-4-yl]-cyclopropane- carboxylic acid (CHF 5071); l-(2,3',4'-trifluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF 5073); l-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5074); l-(3',5'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF 5075); l-(3'-chloro-2,4'-difluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF
5076); l-(4-benzo[b]thiophen-3-yl-3-fluorophenyl)cycloproρanecarboxylic acid
(CHF 5077); 1 -(2-fluoro-4'-ρrop-2-inyloxy-biphenyl-4-yl)-cyclopropanecarboxylic acid
(CHF 5078); l-(4'-cyclohexyloxy-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid
(CHF 5079); l-[2-fluoro-4'-(tetrahydropyran-4-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (CHF 5080); l-[2-fluoro-4'-(4-oxo-cyclohexyl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
(CHF 5081);
2-(2"-fluoro-4-hydroxy- [ 1 , 1 ' :4', 1 "]tert-phenyl-4"-yl)-cyclopropanecarboxylic acid (CHF 5083); l-[4'-(4,4-dimethylcyclohexyl)-2-fluoro[l, -biphenyl]-4-yl]-cyclopropane- carboxylic acid (CHF 5084); l-[2-fluoro-4'-[[4-(trifluoromethyl)benzoyl]ammino][l, l'-biρhenyl]-4-yl]- cyclopropanecarboxylic acid (CHF 5094); l-[2-fluoro-4'-[[4-(trifluoromethyl)cyclohexyl]oxy][l, -biphenyl]-4-yl]- cyclopropanecarboxylic acid (CHF 5096); l-[2-fluoro-4'-[(3,3,5,5-tetramethylcyclohexyl)oxy][l, l'-biρhenyl]-4-yl]- cyclopropanecarboxylic acid (CHF 5102); l-[4'-[(4,4-dimethylcyclohexyl)oxy]-2-fluoro[l, l'-biphenyl]-4-yl]- cyclopropanecarboxylic acid (CHF 5103);
1 -(2,3 ',4"-trifiuoro[ 1 , 1 ' :4', 1 "-tert-phenyl]-4-yl)-cyclopropanecarboxylic acid
(CHF 5104); l-(2,2',4"-trifluoro[l,r:4',l"-tert-phenyl]-4-yl)-cyclopropanecarboxylic acid (CHF 5105); l-(2,3'-difluoro-4"-hydroxy[l, r:4', l "-tert-phenyl]-4-yl)-cyclopropane- carboxylic acid (CHF 5106); l-(2,2'-difluoro-4"-hydroxy[l, :4',l"-tert-ρhenyl]-4-yl)-cyclopropane- carboxylic acid (CHF 5107); 2-(2-fluoro-3',5'-bis(chloro)biphen-4-yl)propionic acid amide (CHF 5125).
A more preferred group of compounds is that in which R and Ri form a
3 carbon atoms ring with the carbon atom to which they are linked;
R2 is fluorine;
G is COOH; Ar is phenyl substituted with one or more groups in such a way as that the log
P (the partition coefficient between n-octanol and water) of the whole molecule is equal or higher than 4.5 as calculated in silico by using the software QikProp® release version 2.1 (Schrodinger Inc). It has indeed been found that the higher the log P of the molecule, the greater is the inhibition potency of the release of Aβ42 peptide and that particularly potent compounds are those whose log P is equal or higher than 4.5, preferably higher than 5.0. Examples of these compounds are CHF 5022, CHF 5074, CHF 5096,
CHF 5105, CHF 5106 and CHF 5107.
The invention also relates to the pharmaceutically acceptable salts and esters prepared in order to increase the crossing of the hemato-encephalic barrier. A further object of the present invention are the compounds of formula
(I) as medicaments, in particular the use thereof in the preparation of pharmaceutical compositions for the treatment and/or the prevention of neurodegenerative diseases such as Alzheimer's disease.
Still a further object of the invention are solid or liquid pharmaceutical compositions, preferably for the oral use, comprising at least one compound of formula (I) in admixture with pharmaceutically acceptable excipients and/or carriers, for example those described in Remington's Pharmaceutical Sciences
Handbook, XVII Ed., Mack Pub., N.Y., U.S.A..
The compounds of general formula (I) wherein R" is H can be prepared according to methods of literature by palladium-catalyzed reaction between an aryl halide of formula (II)
Figure imgf000011_0001
in which R, RΪ and R2 are as defined above and X is bromine or iodine, preferably iodine, with a boronic acid or ester ArB(OL)2 in which L is an alkyl chain, under the conditions reported in Scheme 1.
Figure imgf000012_0001
DME = 1,2-dimethoxyethane TTP = triphenylphosphine
Scheme 1
The compounds of formula (II) are commercially available, or can be prepared according to the following synthetic routes. Derivatives in which R and Rj_ are straight or branched Cr-C alkyl (Ha).
Said compounds can be prepared according to the synthetic route shown in Scheme 2 , starting from the arylacetic acids of formula (III) in which R and R2 are as defined above and X is bromine or iodine.
The acid of formula (III) is esterified, alkylated, and optionally hydrolysed if the group G in the final product is COOH.
Figure imgf000012_0002
Scheme 2 Derivatives in which R and R^ form a 3-6 carbon ring with the carbon atom to which they are linked (lib)
Said compounds are either commercially available, or can be prepared according to the synthetic route reported in Scheme 3 in which n is an integer of 1 to 4.
Figure imgf000013_0001
(lib)
Figure imgf000013_0002
Scheme 3 Boronic acids or the corresponding boronates are either commercially available or can be prepared from the corresponding halide according to methods known in literature.
The compounds of formula (I) wherein G is COOR", where R" is linear or branched C1-C4 alkyl, C3-C6 cycloalkyl or ascorbyl, can be prepared by esterifying the compounds of formula (I) in which G is COOH.
The compounds of formula (I) in which G is CONH2 or CONHSO2R'" where R'" is linear or branched C1-C4 alkyl or C3-C6 cycloalkyl can be prepared by reaction of the corresponding esters with NH3 or the amine NH2SO2R"'. The compounds of formula (I) in which G is tetrazolyl can be prepared from compounds of formula (I) according to known methods, for example transforming the carboxylic acid into amide, dehydrating the amide to nitrile and reacting the latter with tributyltin azide. EXAMPLES
EXAMPLES OF CHEMICAL PREPARATION
Example 1 - Preparation 2-methyl-2-(2-jFluoro-41-trifluoromethylbiphen-4- vDpropionic acid (CHF 4810) Preparation of methyl [2-(2-fluoro-4'-trifluoromethylbiphen-4-yl)lpropionate
A solution of 2-(2-fluoro-4'-trifluoromethylbiphenyl-4-yl)propionic acid
(0.2 g, 0.64 mmoles) in methanol (3 ml) is added with 98% sulfuric acid (0.5 g) and refluxed for 2.5 hours. The solvent is removed under vacuum, the residue is taken up with ethyl acetate (5 ml) and washed with a 5% NaHCO3 solution (5 ml), then with water. The solution is dried over Na2SO and concentrated under vacuum to afford an oil (0.2 g, 95%). HPLC - UV purity (215 nm): 99%
Preparation of methyl ["2-methyl-2-(2-fluoro-4'-trifluoromethylbiphen-4- yPlpropionate A solution of methyl [2-(2-fluoro-4'-trifluoromethylbiphen-4- yl)]ρroρionate (0.2 g, 0.61 mmoles) in anhydrous THF (3 ml) at 0°C and under nitrogen atmosphere, is added with 60% NaH (30 mg, 0.75 mmoles). The mixture is stirred for 30 minutes and added with CH3I (70 μl, 0.91 mmoles). After 3h the mixture is concentrated under vacuum and taken up with ethyl acetate (5 ml). The resulting solution is washed with a 5% NaHCO3 solution (5 ml), then with water, dried over Na2SO4, concentrated under vacuum to give an oil (0.18 g, 87%) which is used for the subsequent reaction without further purification. Preparation of 2-methyl-2-(2-fluoro-4'-trifluoromethylbiphen-4-yl propionic acid
A solution of methyl [2-methyl-2-(2-fluoro-4'-trifluoromethylbiphen-4- yl)]ρroρionate (0.18 g, 0.53 mmoles) in ethanol (5 ml) is added with KOH (60 mg, 1 mmol) and kept under stirring for 3h at room temperature. The mixture is diluted with H2O (5 ml) and the solution is washed with ethyl ether (5 ml). The organic phase is discarded. The aqueous phase is acidified to pH=2 with HCl, then extracted with ethyl acetate (10 ml). The organic phase is dried over Na2SO4 and concentrated under vacuum to give a white solid, which is purified by flash chromatography on SiO2 (eluent hexane/ethyl acetate 8/2 v/v) to obtain the product as a white solid (16 mg, 10%). HPLC - UV purity (215 nm): 97%.
1H NMR (DMSO-d6): 12.56 (s br, 1H); 7.84 (d, 2H); 7.78 (d, 2H); 7.57 (dd, 1H); 7.32 (s, 1H); 7.29 (m, 1H); 1.52 (s, 6H); MS (EI): 326 m/z (M+.), 281, 253.
Following the same procedure and using the suitable reactive, compound, CHF 4961 was prepared.
Example 2 - Preparation of l-(2-fluorobiphenyl-4-vDcycIopropanecarboxylic acid (CHF 5041) Preparation of 4-bromo-3-fluorobenzyl bromide
A solution of 4-bromo-3-fluorotoluene (10 g, 0.053 moles) in carbon tetrachloride (100 ml) is added with N-bromosuccinimide, (NBS; 14 g, 0.08 moles). The mixture is refluxed, added with dibenzoyl peroxide (100 mg, 0.4 mmoles), refluxed for 1 hour, then cooled at room temperature and extracted with water. The aqueous phase is discarded, the organic phase is washed with brine, dried over sodium sulfate and concentrated under vacuum to give an oil (16 g) which is subjected to chromatography on a silica gel column (150 g), eluting with hexane, to afford the product. Preparation of 4-bromo-3-fluorophenylacetonitrile A solution of 4-bromo-3-fluorobenzyl bromide (12.2 g, 0.03 moles) in ethanol (100 ml) is added with NaCN (2 g, 0.04 moles) and refluxed for 2 hours. The mixture is concentrated under vacuum; the resulting residue is taken up with water, then extracted with ethyl acetate. The organic phase is washed with brine, dried over sodium sulfate and concentrated under vacuum to give a dark oil (10 g), which is subjected to chromatography on a silica gel column (150 g), eluting with hexane:ethyl ether 7:3, to afford the product in the solid form. Preparation of 4-bromo-3-fluorophenylcyclopropanenitrile
A solution of 4-bromo-3-fluorophenylacetonitrile (5 g, 23 mmoles) in toluene (20 ml) is added with 35 mmoles of 1,2-dibromoethane, a 50% NaOH aqueous solution (20 ml) and tetrabutyl ammonium bromide (1.6 g, 5 mmoles). The mixture is kept under stirring at room temperature for 5-12 hours, then diluted with water and extracted with ethyl acetate. The organic phase is washed with IN HCl, then with brine, finally dried and concentrated under vacuum to give a brown solid, which is subjected to chromatography on a silica gel column (200 g), eluting with hexane-ethyl ether 1-1, to afford the product in the solid form. Preparation of 4-bromo-3-fluorophenylcycloρroρanecarboxylic acid
A suspension of 4-bromo-3-fluorophenylcycloρropanenitrile (21 mmoles) in methanol (10 ml) is added with a 35% NaOH aqueous solution (40 ml) and a 35% H2O2 aqueous solution (3 ml), then is refluxed for 4 hours, cooled at room temperature and added with 2N HCl (250 ml). The precipitated solid is collected by filtration and redissolved in a 5% NaHCO3 aqueous solution (300 ml). The insoluble fraction is filtered off and the clear filtrate is acidified to pH=2 with 2N HCl. The product precipitates as a white solid, which is recovered by filtration and dried under vacuum. Preparation of l-(2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid 800 mg (3.1 mmoles) of 4-bromo-3-fluorophenylcycloproρanecarbox lic acid and 650 mg (3.4 mmoles) of phenylboronic acid are suspended in 8 ml of a 2M K2CO3 aqueous solution. The mixture is added with tetrabutylammonium bromide (960 mg, 3 mmoles) and palladium(II) acetate (40 mg, 0.18 mmoles) and heated at 130°C in a closed reactor for 30 minutes. After cooling at room temperature, the mixture is added with 2M HCl (25 ml) and extracted with ethyl acetate. The organic phase is washed with IN HCl, then with brine, finally dried and concentrated under vacuum to give an oil (1.7 g), which is crystallized from isopropyl ether-hexane to afford the product as a white solid (0.2 g). HPLC (215 nm) 98%.
MS (El; TSQ 700; parameters 180 C; 70 V; 200 uA): 256 (M+.); 210; 196. *H-NMR (DMSO): 12.41 (s br, 1H); 7.56-7.35(m, 6H); 7.27(m, 1H); 7.24 (s, 1H); 1.48(m, 2H); 1.22(m, 2H).
Following the same procedure as described in Example 1, starting from the suitable 4-bromophenylcycloalkanecarboxylic acids and using the appropriate reactives, compounds CHF 5022, CHF 5023 CHF 5042, CHF 5045, CHF 5046, CHF 5058, CHF 5059, CHF 5060, CHF 5061, CHF 5070, CHF 5071, CHF 5073, CHF 5074, CHF 5075, CHF 5076, CHF 5077, CHF 5078, CHF 5079, CHF 5080, CHF 5081, CHF 5083, CHF 5084, CHF 5094, CHF 5096, CHF 5102, CHF 5103, CHF 5104, CHF 5105, CHF 5106, CHF 5107 and CHF 5002 were prepared. Example 3 - Pharmacological activity Inhibition of Aβ4? release in the supernatant of H4-15x cells
H4- 15x cells (human neuroglioma cells transfected with the human gene encoding for the precursor of β-amyloid protein APP695) were cultured in flasks (in incubator at 37°C, under aqueous vapour saturated atmosphere with 5% carbon dioxide), in the presence of hygromycin and blasticidin, which maintain the selective pressure for the cells continuously expressing the gene of interest.
When the cells reached about 90% confluency, they were collected and re-seeded in 24 wells plates (2 x 105 cells each), in 0.5 ml of complete culture medium. After approx. 24 hours, when the cells had adhered to the well surface and reached confluency, the medium of each well was replaced with 0.5 ml of fresh culture medium, supplemented with a compound (I) to 100 micromolar final concentration. Each tested concentration was repeated in triplicate. The molecules used for the treatment were previously dissolved in dimethylsulfoxide (DMSO) or in a dimethylsulfoxide/water mixture, the final concentration of DMSO in the wells not exceeding 1%. Thus the prepared plates were incubated again overnight (14-16 hours); afterwards the cell supernatant was taken from each well and Aβ 2 and Aβ 0 proteins were quantitated. The assay was carried out with an instrumentation for microplates chemoluminescence analysis, which allows to separately quantify the two proteins and is based on the immobilization of an analyte-antibody complex on paramagnetic microbeads. One of the antibodies of this complex is marked with a ruthenium compound which, upon electrochemical excitement, gives a light signal, having intensity proportional to the amount of analyte present. Inhibition of cvclooxygenase-1 (COX-1) in rat whole blood
Whole blood was taken from the rat abdominal aorta and immediately placed in heparinized tubes. Aliquots of heparinized blood (500 μl) were preincubated with 100 μM concentration of the tested compounds or with the only carrier (DMSO) for 1 h at 37°C. Eicosanoid production was induced by addition of calcium ionophore A23187 (final concentration 5xl0"5 M) and was interrupted after 30 minute incubation by quickly placing the samples in dry ice. Thereafter, samples were centrifuged (12000 g x 3 minutes a 4°C) and the production of TxB2 thromboxane B2 was calculated by radioimmunoassay. The results expressed as percent inhibition of Aβ 2 release at 100 μM and percent COX-1 inhibitory activity at the same concentration are reported in Table 1. Flurbiprofen used as comparison at the same concentration showed approx. 25% inhibition of Aβ42 release and 100% COX-1 inhibitory activity. Table 1 : Percent inhibition of Aβ42 release and percent COX-1 inhibitory activity of representative compounds of the invention at 100 μM concentration.
Figure imgf000019_0001

Claims

1. Compounds of general formula (I):
Figure imgf000020_0001
wherein:
R and R} are the same and are linear or branched C1-C4 alkyl; or they form a 3 to 6 carbon atoms ring with the carbon atom to which they are linked; G is: a COOR" group wherein R" is H, linear or branched C C4 alkyl, C3-C6 cycloalkyl, or ascorbyl; a CONH2 or a CONHSO2R'" group wherein R'" is linear or branched
C C4 alkyl or C3-C6 cycloalkyl; - a tetrazolyl residue;
R2 is H, CF3) OCF3 or a halogen selected from the group of F, Cl, Br, I, preferably fluorine.
Ar is a group of formula
Figure imgf000020_0002
wherein R3 represents one or more groups independently selected from: halogen as previously defined;
CF3;
C3-C8 cycloalkyl optionally substituted with one or more C C4 alkyl and/or oxo groups;
CH=CH2;
CN;
CH2OH; - methylendioxy or ethylendioxy;
NO2 phenyl optionally substituted with one or more of the following groups: halogen; CF3; OCF3; OH; linear or branched Cι-C4 alkyl; a saturated eterocycle with at least 4 carbon atoms and at least 1 heteroatom; C3-C8 cycloalkyl in turn optionally substituted with one or more of the following groups linear or branched C1-C4 alkyl, CF3 or OH;
OR4 or NHCOR4 wherein R is CF3, linear or branched C2-C6 alkenyl or alkynyl; benzyl; phenyl optionally substituted with one or more of the following groups: halogen, CF3, OCF3, OH, linear or branched C C4 alkyl; a saturated eterocycle with at least 4 carbon atoms and at least 1 heteroatom; C3-C8 cycloalkyl in turn optionally substituted with one or more of the following groups: linear or branched C1-C4 alkyl, CF3 or
OH;
SR5, SO2R5 or COR5 wherein R5 is linear or branched C C6 alkyl; otherwise Ar is an eterocycle ring selected from the group of thiophene, benzothiophene, dibenzothiophene, thianthrene, pyrrole, pyrazole, furan, benzofuran, dibenzofuran, indole, isoindole, benzofurane, imidazole, benzoimidazole, oxazole, isoxazole, benzoxazole, thiazole, pyridine, pyrimidine, pyrazine, pyridazine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, pyrazole, pyran, benzopyran, pyrrolizine, phtalazine, 1,5-naphthyridine, 1,3-dioxole, 1,3-benzodioxole, optionally substituted with one or more groups R3 as defined above; pharmaceutically acceptable salts and other esters thereof.
2. Compounds as claimed in claim 1, wherein R and Ri form a 3 carbon atom ring with the carbon atom to which they are linked; R2 is fluorine; G is a COOR" group in which R" is H, linear or branched C C4 alkyl, C3-C6 cycloalkyl or ascorbyl; Ar is phenyl as defined in claim 1.
3. Compounds as claimed in claim 1, wherein R and R form a 3 carbon atom cycle with the carbon atom to which they are linked; R2 is fluorine; G is a CONH2 or CONHSO2R'" in which R"' is linear or branched Cι-C4 alkyl or C3-C6 cycloalkyl; Ar is phenyl as defined in claim 1.
4. Compounds as claimed in claim 1, wherein both R and Ri are CH3; R2 is fluorine; G is COOR" in which R" is as defined in claim 1; Ar is phenyl as defined in claim 1.
5. Compounds as claimed in claim 1, wherein voth R and R.γ are CH3; R2 is fluorine; G is a CONH2 or CONHSO2R"' in which R'" is as defined above; Ar is phenyl substituted with an optionally substituted phenyl.
6. Compounds as claimed in claim 1, wherein R and R! form a 3 carbon atoms ring with the carbon atom to which they are linked; R2 is fluorine; G is a COOR" group in which R" is as defined above; Ar is a heterocycle as defined in claim 1.
7. Compounds as claimed in claim 1, wherein both R and Ri are CH3; G is a COOR" group in which R" is as defined above; R2 is fluorine; Ar is a heterocycle as defined in claim 1.
8. Compounds as claimed in claim 1 wherein R and Rj form a 3 carbon atoms ring with the carbon atom to which they are linked; G is COOH; R is fluorine; Ar is phenyl substituted with one or more groups in such a way as that the log P of the whole molecule is equal or higher than 4.5 as calculated in silico by using the software QikProp® release version 2.1 (Schrodinger Inc).
9. Compounds as claimed in claim 8 selected from the group of CHF 5022, CHF 5074, CHF 5096, CHF 5105 and CHF 5106 and CHF 5107.
10. Compounds as claimed in claims 1-9 as medicaments.
11. Pharmaceutical compositions containing a compound of formula (I) in admixture with pharmaceutically acceptable carriers and/or excipients.
12. Pharmaceutical compositions as claimed in claim 11, for the oral administration.
13. The use of the compounds of formula (I) as claimed in claims 1 to 9, for the preparation of a medicament for the treatment of diseases connected with an increased production of neurotoxic peptide Aβ42.
14. The use of the compounds of formula (I) as claimed in claims 1 to 9, for the preparation of a medicament for the preventive or therapeutical treatment of neurodegenerative diseases.
15. The use of the compounds of formula (I) as claimed in claim 14, for the treatment of Alzheimer's disease.
PCT/EP2004/001596 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases WO2004074232A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2514384A CA2514384C (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
BRPI0407662A BRPI0407662B8 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
SI200430900T SI1594833T1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
US10/546,190 US7662995B2 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
DE602004016729T DE602004016729D1 (en) 2003-02-21 2004-02-19 1-PHENYLALKANCARBONIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP04712483A EP1594833B1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
KR1020117008239A KR101152448B1 (en) 2003-02-21 2004-02-19 Preparation method of 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
DK04712483T DK1594833T3 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU2004213145A AU2004213145B2 (en) 2003-02-21 2004-02-19 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
KR1020057014850A KR101088272B1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2006501896A JP4472691B2 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
NO20053855A NO333118B1 (en) 2003-02-21 2005-08-18 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
HK06107643.0A HK1087398A1 (en) 2003-02-21 2006-07-07 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
US12/647,069 US8022250B2 (en) 2003-02-21 2009-12-24 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
US13/204,989 US8314268B2 (en) 2003-02-21 2011-08-08 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2003A000311 2003-02-21
ITMI20030311 ITMI20030311A1 (en) 2003-02-21 2003-02-21 2-FENYL-2-DIALKYL-ACETIC ACIDS FOR THE TREATMENT OF ALZHEIMER DISEASE.
ITMI20032068 ITMI20032068A1 (en) 2003-10-23 2003-10-23 DERIVATIVES OF 1-PHENYLCYCLOALCANCARBOSSYIC ACID FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
ITMI2003A002068 2003-10-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/546,190 A-371-Of-International US7662995B2 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
US12/647,069 Continuation US8022250B2 (en) 2003-02-21 2009-12-24 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
WO2004074232A1 true WO2004074232A1 (en) 2004-09-02
WO2004074232A8 WO2004074232A8 (en) 2005-09-09

Family

ID=32910543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001596 WO2004074232A1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Country Status (17)

Country Link
US (3) US7662995B2 (en)
EP (1) EP1594833B1 (en)
JP (1) JP4472691B2 (en)
KR (2) KR101152448B1 (en)
AT (1) ATE409176T1 (en)
AU (1) AU2004213145B2 (en)
BR (1) BRPI0407662B8 (en)
CA (1) CA2514384C (en)
CY (1) CY1108514T1 (en)
DE (1) DE602004016729D1 (en)
DK (1) DK1594833T3 (en)
ES (1) ES2312964T3 (en)
HK (1) HK1087398A1 (en)
NO (1) NO333118B1 (en)
PT (1) PT1594833E (en)
SI (1) SI1594833T1 (en)
WO (1) WO2004074232A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133322A1 (en) 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011015287A2 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011120778A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Novel polymorphs and salts
US20110263711A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2011151330A1 (en) 2010-06-04 2011-12-08 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
EP2404607A1 (en) * 2006-10-10 2012-01-11 Infinity Pharmaceuticals, Inc. Boronic acids and esters as inhibitors of fatty acid amide hydrolase
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2013150072A1 (en) 2012-04-04 2013-10-10 Chiesi Farmaceutici S.P.A. Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2014206897A2 (en) 2013-06-24 2014-12-31 Zach System S.P.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
WO2014206898A1 (en) 2013-06-24 2014-12-31 Chiesi Farmaceutici S.P.A. Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
WO2015181094A1 (en) 2014-05-26 2015-12-03 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
US9771378B2 (en) 2014-01-15 2017-09-26 Denali Therapeutics, Inc. Fused morpholinopyrimidines and methods of use thereof
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
US9951089B2 (en) 2010-02-03 2018-04-24 Infinity Pharmaceuticals, Inc. Methods of treating a fatty acid amide hydrolase-mediated condition

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR101152448B1 (en) * 2003-02-21 2012-07-02 키에시 파르마슈티시 엣스. 피. 에이. Preparation method of 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2007528857A (en) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド Pharmaceutical methods, dosing regimens and dosage forms for the treatment of Alzheimer's disease
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (en) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 Veneers for walls, retaining walls and the like
BRPI0513647A (en) 2004-08-03 2008-05-13 Chiesi Farma Spa 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (en) * 2004-08-11 2008-06-10 Myriad Genetics Inc pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US20150320706A1 (en) 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
MX2024002472A (en) 2021-08-31 2024-03-12 Cerespir Incorporated Co-crystals.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746751A (en) * 1968-07-04 1973-07-17 Takeda Chemical Industries Ltd 1-(3-chloro-4-cycloalkylphenyl)-cyclo-alkyl-1-carboxylic acids
JPS5046669A (en) * 1973-03-28 1975-04-25
JPS58177977A (en) * 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd 4-phenylpyrazole
JPH0994680A (en) * 1995-07-24 1997-04-08 Toyota Motor Corp Friction welding equipment
WO1999041224A1 (en) * 1998-02-13 1999-08-19 Merck Frosst Canada & Co. Biaryl-acetic acid derivatives and their use as cox-2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4994680A (en) 1973-01-22 1974-09-09
WO1996002529A1 (en) * 1994-07-13 1996-02-01 Taisho Pharmaceutical Co., Ltd. Thiopheneacetic acid derivative
AU2001257022B2 (en) 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US7332516B2 (en) * 2003-01-14 2008-02-19 Merck + Co., Inc. Geminally di-substituted NSAID derivatives as Aβ42 lowering agents
KR101152448B1 (en) * 2003-02-21 2012-07-02 키에시 파르마슈티시 엣스. 피. 에이. Preparation method of 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
BRPI0513647A (en) * 2004-08-03 2008-05-13 Chiesi Farma Spa 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746751A (en) * 1968-07-04 1973-07-17 Takeda Chemical Industries Ltd 1-(3-chloro-4-cycloalkylphenyl)-cyclo-alkyl-1-carboxylic acids
JPS5046669A (en) * 1973-03-28 1975-04-25
JPS58177977A (en) * 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd 4-phenylpyrazole
JPH0994680A (en) * 1995-07-24 1997-04-08 Toyota Motor Corp Friction welding equipment
WO1999041224A1 (en) * 1998-02-13 1999-08-19 Merck Frosst Canada & Co. Biaryl-acetic acid derivatives and their use as cox-2 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "4-Phenylpyrazoles", XP002286239, retrieved from STN Database accession no. 1984:85691 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKANISHI, MICHIO ET AL: "Phenylacetic acids", XP002286241, retrieved from STN Database accession no. 1975:156085 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKANISHI, MICHIO ET AL: "Pyridylphenylalkanoic acids", XP002286252, retrieved from STN Database accession no. 1976:105414 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404607A1 (en) * 2006-10-10 2012-01-11 Infinity Pharmaceuticals, Inc. Boronic acids and esters as inhibitors of fatty acid amide hydrolase
US8664249B2 (en) 2007-12-20 2014-03-04 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8367863B2 (en) 2007-12-20 2013-02-05 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009149797A1 (en) * 2008-06-11 2009-12-17 Chiesi Farmaceutici S.P.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
RU2502721C2 (en) * 2008-06-11 2013-12-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Method of producing 1-(2-halogen biphenyl-4-yl)-cyclopropane carboxylic acid derivatives
AU2009256959B2 (en) * 2008-06-11 2014-03-27 Chiesi Farmaceutici S.P.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
EP2133322A1 (en) 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
US20110039934A1 (en) * 2009-08-04 2011-02-17 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2- halobiphenyl-4-yl)-cyclopropanecarboxylic acid
US9056818B2 (en) 2009-08-04 2015-06-16 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011015287A3 (en) * 2009-08-04 2011-03-31 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011015287A2 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
AU2010281069B2 (en) * 2009-08-04 2015-09-10 Chiesi Farmaceutici S.P.A. Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
US9951089B2 (en) 2010-02-03 2018-04-24 Infinity Pharmaceuticals, Inc. Methods of treating a fatty acid amide hydrolase-mediated condition
RU2573384C2 (en) * 2010-04-01 2016-01-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Novel polymorphs and salts
EP2647618A1 (en) 2010-04-01 2013-10-09 CHIESI FARMACEUTICI S.p.A. Novel polymorphs and salts
US8673978B2 (en) 2010-04-01 2014-03-18 Chiesi Farmaceutici S.P.A. Polymorphs and salts
WO2011120778A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Novel polymorphs and salts
WO2011131661A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
US9150489B2 (en) * 2010-04-21 2015-10-06 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
US20110263711A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2011151330A1 (en) 2010-06-04 2011-12-08 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
CN104169251A (en) * 2012-04-04 2014-11-26 奇斯药制品公司 Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases
US8835494B2 (en) 2012-04-04 2014-09-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-(2-halo-biphenyl-4-yl)-Alkanecarboxylic for the treatment of neurodegenerative diseases
WO2013150072A1 (en) 2012-04-04 2013-10-10 Chiesi Farmaceutici S.P.A. Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2014206897A2 (en) 2013-06-24 2014-12-31 Zach System S.P.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
EP2818460A1 (en) 2013-06-24 2014-12-31 ZaCh System S.p.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
WO2014206898A1 (en) 2013-06-24 2014-12-31 Chiesi Farmaceutici S.P.A. Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
US9771378B2 (en) 2014-01-15 2017-09-26 Denali Therapeutics, Inc. Fused morpholinopyrimidines and methods of use thereof
WO2015181094A1 (en) 2014-05-26 2015-12-03 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof

Also Published As

Publication number Publication date
DE602004016729D1 (en) 2008-11-06
EP1594833B1 (en) 2008-09-24
NO20053855D0 (en) 2005-08-18
KR20110057227A (en) 2011-05-31
US20100099768A1 (en) 2010-04-22
US8314268B2 (en) 2012-11-20
WO2004074232A8 (en) 2005-09-09
CY1108514T1 (en) 2014-04-09
US20110288175A1 (en) 2011-11-24
BRPI0407662B1 (en) 2019-11-12
DK1594833T3 (en) 2008-12-15
HK1087398A1 (en) 2006-10-13
US7662995B2 (en) 2010-02-16
US20070060752A1 (en) 2007-03-15
JP2006518351A (en) 2006-08-10
KR101152448B1 (en) 2012-07-02
ATE409176T1 (en) 2008-10-15
SI1594833T1 (en) 2008-12-31
BRPI0407662B8 (en) 2021-05-25
JP4472691B2 (en) 2010-06-02
NO20053855L (en) 2005-11-21
ES2312964T3 (en) 2009-03-01
AU2004213145B2 (en) 2010-05-13
NO333118B1 (en) 2013-03-04
BRPI0407662A (en) 2006-03-01
CA2514384C (en) 2012-04-10
AU2004213145A1 (en) 2004-09-02
KR101088272B1 (en) 2011-11-30
CA2514384A1 (en) 2004-09-02
PT1594833E (en) 2008-12-03
US8022250B2 (en) 2011-09-20
KR20050104369A (en) 2005-11-02
EP1594833A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
EP1594833B1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1778623B1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
JPH0249759A (en) Production of optically active substituted benzyl alcohol
DE69030202T2 (en) Phenylalkane (s) acids with leukotriene B4 antagonistic effect
WO2004073705A1 (en) 1-phenyl-2- monoalkyl carboxylic acid derivatives for the treatment of neurodegenerative diseases
FR2486955A1 (en) TYPE A SMOTIC LIQUID CRYSTAL HAVING POSITIVE DIELECTRIC ANISOTROPY
ZA200506614B (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
Peretto et al. Raveglia et al.(45) Date of Patent: Nov. 20, 2012
Peretto et al. Raveglia et a].(45) Date of Patent: Sep. 20, 2011
EP0665212B1 (en) Process for the preparation of 2,4,6-trimethylphenylacetic acid
US4304930A (en) Process for the preparation of 2-(3-phenoxy-phenyl)-propionic acid
WO2024114665A1 (en) Substituted triazine-2,4-dione derivative intermediate and preparation method therefor
CN118619885A (en) Arylimidazole compound and medical application thereof
JP2704911B2 (en) Liquid crystal compound containing pyridine ring
JPS6154015B2 (en)
JPS5819662B2 (en) Method for producing 2↓-hydroxy↓-3↓-butenoic acid derivative
FR2504129A1 (en) NEW PROCESS FOR OBTAINING AROMATIC NITRILES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020057014850

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005/06614

Country of ref document: ZA

Ref document number: 2514384

Country of ref document: CA

Ref document number: 2004213145

Country of ref document: AU

Ref document number: 200506614

Country of ref document: ZA

Ref document number: 2006501896

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048047290

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004712483

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004213145

Country of ref document: AU

Date of ref document: 20040219

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213145

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 36/2004 UNDER (72, 75) REPLACE "PERETTO, LLARIA" BY "PERETTO, ILARIA"

WWP Wipo information: published in national office

Ref document number: 1020057014850

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004712483

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407662

Country of ref document: BR

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007060752

Country of ref document: US

Ref document number: 10546190

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10546190

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004712483

Country of ref document: EP